Emcure Pharmaceuticals has announced the acquisition of Cutimed Inc., a Canadian company specialising in cosmetics and personal care products. The acquisition, valued at up to CAD $5.05 million, was executed through Emcure’s step-down subsidiary, Mantra Pharma Inc., which is a subsidiary of Marcan Pharmaceuticals Inc. This strategic move aligns with Emcure’s long-term growth strategy to enhance its presence in the Canadian dermatological and cosmetic product segments.
Cutimed Inc., incorporated in Québec, Canada, has been operational since 2011, focusing on the development and commercialisation of cosmetic and dermatological products, including creams, cleansers, and lip care products. The company reported an annual turnover of CAD $2.8 million, primarily from the Canadian market.
The acquisition does not constitute a related party transaction, as neither the promoter, promoter group, nor group companies of Emcure had any prior interest in Cutimed. The acquisition and subsequent amalgamation with Mantra Pharma Inc. are expected to strengthen Emcure’s portfolio in the Canadian market and support its long-term growth strategy.
Following the acquisition, Cutimed has been amalgamated with Mantra Pharma Inc. effective April 01, 2026, using the short-form amalgamation procedure under the Business Corporations Act (Québec). This amalgamation aims to consolidate Emcure’s Canadian operations and achieve operational and administrative efficiencies.
The acquisition was completed with cash consideration, and no government approvals were required beyond customary conditions and compliance with applicable Canadian laws. Emcure’s acquisition of Cutimed is a strategic step to bolster its presence in the pharmaceuticals and healthcare industry, particularly in the Canadian market.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).